Clinical Trials Logo

Filter by:
NCT ID: NCT04832958 Recruiting - Prostate Cancer Clinical Trials

Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients

Start date: May 15, 2021
Phase: Phase 2
Study type: Interventional

The project aims at assessing the role of radio-guided surgery in the detection of lymph node invasion (LNI) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) by using an intraoperative gamma probe and a radioactive labelled PSMA ligand (99mTc-PSMA-I&S). We hypothesize that 99mTc-PSMA-I&S radio-guided surgery (99mTc-PSMA-RGS) might assist physicians in the identification of patients with LNI candidate for an extended pelvic lymph node dissection (ePLND). Overall, 100 men with a LNI risk >5% according to the Briganti nomogram will be submitted to 68Ga-PSMA PET/MRI followed by 99mTc-PSMA-RGS and ePLND. The aims are 1) to assess the safety and tolerability of 99mTc-PSMA-I&S; 2) to assess the accuracy of 99mTc-PSMA-RGS in the identification of LNI compared to available clinical tools and to molecular imaging (i.e., 68Ga-PSMA PET/MRI); 3) to assess whether 99mTc-PSMA-RGS would allow for the identification of positive nodes outside the standard ePLND template.

NCT ID: NCT04832607 Recruiting - Clinical trials for Stem Cell Transplant Complications

Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

TRACE
Start date: August 27, 2019
Phase: Phase 3
Study type: Interventional

Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. Adoptive transfer of virus-specific T cells is an attractive approach to restore protective T-cell immunity in patients with refractory viral infections after allogeneic HSCT. The aim of this Phase III trial is to confirm efficacy of this treatment in children and adults.

NCT ID: NCT04832555 Recruiting - Clinical trials for Squamous Cell Carcinoma of Head and Neck

Non Elective Vulnerable Elderly Radiotherapy

NEVER
Start date: February 20, 2021
Phase: N/A
Study type: Interventional

To evaluate whether patients defined "non-fit for curative non-surgical radio-chemotherapy" and therefore treated with RT alone addressed only to non-elective sites of disease, could obtain a non-inferior loco-regional control compared to similar historical cohorts.

NCT ID: NCT04832178 Recruiting - Clinical trials for Major Depressive Disorder

Sumor as Adjuvant Therapy in Treatment-resistant Major Depression

SUSCA
Start date: June 1, 2021
Phase: Phase 4
Study type: Interventional

Sumor is a food supplement that combines the main coenzymes of the S-Adenosyl methionine (SAMe) cycle, namely vitamins B6, B12 and folate, with SAMe and betaine. Sumor also contains vitamin C, a molecule that has shown promise in the treatment of depression in experimental models, and selenium, an antioxidant agent whose blood deficiency has been associated with depressive symptoms in some preliminary studies. There are no studies in the literature on the efficacy of this combination in the adjuvant therapy of depression. The purpose of this study is to compare the effects of Sumor in co-therapy with an SSRI antidepressant versus co-therapy with placebo in patients with treatment-resistant Major Depressive Disorder.

NCT ID: NCT04831983 Recruiting - Prostate Cancer Clinical Trials

ABlative Radiotherapy (for) Unfavorable Prostate Tumors

ABRUPT
Start date: April 15, 2021
Phase:
Study type: Observational

Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy tissues is critically assessed with fulfillment of strict constraints and dose distribution is accomplished using image guidance and tracking tools. In the present trial, intermediate unfavorable and selected high-risk organ-confined prostate cancer patients will undergo Single Dose Radiation Therapy (SDRT) With Focal Boost to the MRI-defined Macroscopic Tumor Volume by means of image-guided volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) and state-of-the-art treatment-planning and quality assurance procedures. Androgen Deprivation Therapy (ADT) type and duration has been set as per standard of care, in accordance with current recommendations and guidelines.

NCT ID: NCT04831970 Recruiting - Radiation Toxicity Clinical Trials

POst-Prostatectomy Ablative Radiation Therapy

POPART
Start date: April 15, 2021
Phase:
Study type: Observational

The use of hypofractionated radiotherapy for prostate cancer has matured to a point that in current guidelines extremely hypofractionated image-guided IMRT regimens (6 Gy per fraction or greater) can be considered an alternative to conventionally fractionated regimens at clinics with appropriate technology, physics and clinical expertise. The delivery of fewer and larger fractions with hypofractionation compared to conventional radiotherapy might effectively improve the therapeutic ratio while maintaining isoeffective tumour doses, thus, shortening overall treatment time. In the present study, patients will undergo postoperative image-guided SBRT by means of volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with state-of-the-art treatment-planning and quality assurance procedures. Normal tissue sparing and delivery accuracy are accomplished by the use of devices that ensure stability and beam location reproducibility. The primary endpoint is to evaluate the cumulative incidence of treatment related toxicities and adverse events in the acute (< 90 days from the end of treatment) and late (> 90 days) setting.

NCT ID: NCT04831606 Recruiting - Diabetic Foot Ulcer Clinical Trials

Blue Light Photobiomodulation Therapy on Neuroischemic Patients

HERMES
Start date: July 31, 2021
Phase: N/A
Study type: Interventional

This is a pilot case/control clinical study on a group of outpatients with diabetic foot lesions aiming to verify the efficacy and safety of the Blue light photobiomodulation therapy with EmoLED medical device, in addition to standard therapy compared to the standard therapy alone, evaluating the percentage of healed lesions (which have reached complete and lasting re-epithelialization), the evaluation of the healing time and reduction of the ulcerated area during the time of observation, the perception of pain and the quality of life of the enrolled patients. The aim of this study is therefore to determine any differences in outcome between the two groups considered and, in particular, if the therapy of the group being treated is more effective than the standard therapy in terms of percentage of healed lesions, healing time, and reduction of the ulcerated area, pain perception, and quality of life, and is at least as safe in terms of occurrence of adverse events.

NCT ID: NCT04830904 Recruiting - Ataxia, Cerebellar Clinical Trials

Efficacy of Lycra Garments in Ataxic Subjects

Start date: August 3, 2020
Phase: N/A
Study type: Interventional

The aim of this study iss to analyze the effect of Lycra garments in the axial stabilization in subjects affected by ataxia, both in acquired cerebellar injuries and malformative etiology. Improvement are expected for what concerns: - greater stability during stance - smoother walking pattern - reduction of risk of fall. The two groups (acquired and malformative) will be compared.

NCT ID: NCT04830774 Recruiting - COVID-19 Clinical Trials

Natural History of COVID-19-Related Atrial Fibrillation

unCOVer-AF
Start date: April 15, 2021
Phase: N/A
Study type: Interventional

The unCOVer-AF prospective, multicenter registry aims at determining the natural history of atrial fibrillation (AF) via continuous cardiac rhythm monitoring in patients with a first arrhythmic episode during COVID-19 hospitalization.

NCT ID: NCT04830124 Recruiting - Cutaneous Melanoma Clinical Trials

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6

ARTISTRY-6
Start date: May 27, 2021
Phase: Phase 2
Study type: Interventional

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy